External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Roche and Genentech at

ESMO Asia 2022

December 02 - December 04

Singapore, Republic of Singapore / Virtual (Hybrid)

esmo.org

Add to calendar

Medical Materials

Agenda

Coming soon

09:00 AM

Duration 5mins Hall 404

The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase 3, randomised FDChina study

Shao Z, Huang T, Fan Z, Wang Y, Yan X, Yang H, Wang S, Pang D, Li H, Wang H, Geng C, Huang L, Siddiqui A, Wang B, Xie B, Sun G, Restuccia E

Oncology | Breast Cancer

Add to calendar

09:37 AM

Duration 5mins Hall 406

Alectinib vs crizotinib in Asian patients with treatment-naïve advanced ALK+ non-small cell lung cancer: 5-year update from the Phase 3 ALESIA study

Zhou C, Lu Y, Kim S-W, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang J-J, Cheng Y, Lee S-H, Chang J, Fang J, Liu Z, Bu L, Qian G, Xu T, Archer V, Hilton M, Zhou M, Zhang L

Oncology | Lung Cancer

Add to calendar

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.